Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non –Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers

In conclusion, tropifexor was well tolerated, had a pharmacokinetic profile suitable for on ce‐daily dosing and showed dose‐dependent target engagement without altering plasma lipids in healthy volunteers.

Source: Clinical Pharmacology in Drug Development - December 9, 2019 Category: Drugs & Pharmacology Authors: Michael K. Badman, Jin Chen, Sachin Desai, Soniya Vaidya, Srikanth Neelakantham, Jie Zhang, Lu Gan, Kate Danis, Bryan Laffitte, Lloyd B. Klickstein Tags: Original Manuscript Source Type: research